Morgan E. Grams

Nephrology

1830 E Monument St Ste 416
Baltimore, MD 21287

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 471 publications

Metabolomic Signatures of Inflammation in Chronic Kidney Disease.

Metabolomic Signatures of Inflammation in Chronic Kidney Disease.

Journal: Kidney medicine

Published: August 30, 2026

Metabolites Associated With Long-Term Risk of Peripheral Artery Disease: The ARIC Study.

Metabolites Associated With Long-Term Risk of Peripheral Artery Disease: The ARIC Study.

Journal: Arteriosclerosis, thrombosis, and vascular biology

Published: August 27, 2026

Vision-Language Models for Image-Based Dietary Assessment: A Benchmark of Accuracy, Cost, and Prompt Strategies Across Ten Models.

Vision-Language Models for Image-Based Dietary Assessment: A Benchmark of Accuracy, Cost, and Prompt Strategies Across Ten Models.

Journal: bioRxiv : the preprint server for biology

Published: August 20, 2026

External Validation of the PREVENT Equations in a National Sample of US Adults.

External Validation of the PREVENT Equations in a National Sample of US Adults.

Journal: Circulation. Population health and outcomes

Published: August 05, 2026

Proper Phenotyping of Pancreatic Cancer in Database Research-Reply.

Proper Phenotyping of Pancreatic Cancer in Database Research-Reply.

Journal: JAMA oncology

Published: July 23, 2026

Alzheimer's disease proteome-wide association study implicates adaptive immunity and identifies risk genes LILRB1 and SIRPA.

Alzheimer's disease proteome-wide association study implicates adaptive immunity and identifies risk genes LILRB1 and SIRPA.

Journal: Science translational medicine

Published: July 01, 2026

Diversion of Arginine's dietary metabolic fate in proteinuric kidney disease.

Diversion of Arginine's dietary metabolic fate in proteinuric kidney disease.

Journal: Research square

Published: June 29, 2026

State-Level Variation in GLP-1 Receptor Agonist Use Among Medicaid Beneficiaries Without Diabetes by State Obesity Coverage Policy.

State-Level Variation in GLP-1 Receptor Agonist Use Among Medicaid Beneficiaries Without Diabetes by State Obesity Coverage Policy.

Journal: Diabetes care

Published: June 24, 2026

A Framework for Risk-Based Implementation of Combination Therapy in CKD: Who, Why, When, and How?

A Framework for Risk-Based Implementation of Combination Therapy in CKD: Who, Why, When, and How?

Journal: Clinical journal of the American Society of Nephrology : CJASN

Published: June 23, 2026

Measured and Estimated Glomerular Filtration Rates and Risk of Adverse Health Outcomes.

Measured and Estimated Glomerular Filtration Rates and Risk of Adverse Health Outcomes.

Journal: JAMA

Published: June 04, 2026

Circulating Ephrin-Eph Signaling Reflects Interstitial Fibrosis and Tubular Atrophy in Diabetic Kidney Disease.

Circulating Ephrin-Eph Signaling Reflects Interstitial Fibrosis and Tubular Atrophy in Diabetic Kidney Disease.

Journal: Clinical journal of the American Society of Nephrology : CJASN

Published: April 30, 2026

Authors' Reply: SGLT2 Inhibitors vs GLP-1 Receptor Agonists Type 2 Diabetes, the Kidney Conundrum.

Authors' Reply: SGLT2 Inhibitors vs GLP-1 Receptor Agonists Type 2 Diabetes, the Kidney Conundrum.

Journal: Clinical journal of the American Society of Nephrology : CJASN

Published: April 24, 2026

Showing 1-12 of 471

Last Updated: 09/26/2026